

Resource Summary Report

Generated by [NIF](#) on Sep 7, 2026

NCI-H358

RRID:CVCL_1559

Type: Cell Line

Proper Citation

RRID:CVCL_1559

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1559

Proper Citation: RRID:CVCL_1559

Description: Cell line NCI-H358 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Minimally invasive lung adenocarcinoma

Defining Citation: [PMID:1311061](#), [PMID:1565469](#), [PMID:2386953](#), [PMID:2388294](#), [PMID:3335022](#), [PMID:3940644](#), [PMID:7972006](#), [PMID:8806092](#), [PMID:8806101](#), [PMID:9649128](#), [PMID:11030152](#), [PMID:11369051](#), [PMID:11464291](#), [PMID:12068308](#), [PMID:18083107](#), [PMID:19472407](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20557307](#), [PMID:22460905](#), [PMID:22961666](#), [PMID:24135919](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29444439](#), [PMID:29681454](#), [PMID:30038707](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31803961](#), [PMID:31978347](#), [PMID:34320349](#), [PMID:35117401](#), [PMID:35839778](#)

Comments: Caution: NCI-H358 and NCI-H358M (Cellosaurus=CVCL_JA53) could be identical., Population: Caucasian., Part of: NCI RAS program mutant KRAS cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H358

Synonyms: H358, H-358, NCIH358

Cross References: BTO:BTO_0002835, CLO:CLO_0008085, EFO:EFO_0002291, CLDB:cl3656, AddexBio:C0016016/4968, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-5807, BioGRID_ORCS_Cell_line:964, BioSample:SAMN03471313, BioSample:SAMN10987886, cancercellines:CVCL_1559, CCRID:1101HUM-PUMC000470, CCRID:3101HUMSCSP583, CCRID:3101HUMTCHu151, Cell_Model_Passport:SIDM00718, ChEMBL-Cells:ChEMBL3307543, ChEMBL-Targets:ChEMBL614135, CLS:300430, Cosmic:722039, Cosmic:724875, Cosmic:877106, Cosmic:903573, Cosmic:908465, Cosmic:910563, Cosmic:914944, Cosmic:929970, Cosmic:934545, Cosmic:980963, Cosmic:1004699, Cosmic:1028934, Cosmic:1032435, Cosmic:1052333, Cosmic:1146915, Cosmic:1219075, Cosmic:1239902, Cosmic:1600603, Cosmic:1741780, Cosmic:1802307, Cosmic:1870273, Cosmic:1995575, Cosmic:2042868, Cosmic:2560229, Cosmic:2630418, Cosmic:2647632, Cosmic:2668265, Cosmic-CLP:908465, DepMap:ACH-000860, ECACC:95111733, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, FANTOM5_SSTAR:10709-109H7, GDSC:908465, GEO:GSM108849, GEO:GSM108850, GEO:GSM206491, GEO:GSM253398, GEO:GSM274731, GEO:GSM274732, GEO:GSM385520, GEO:GSM385531, GEO:GSM434257, GEO:GSM513937, GEO:GSM514321, GEO:GSM784251, GEO:GSM794285, GEO:GSM817072, GEO:GSM827468, GEO:GSM844648, GEO:GSM887427, GEO:GSM888507, GEO:GSM1374744, GEO:GSM1670241, IARC_TP53:21571, IARC_TP53:21723, IGRhCellID:NCIH358, KCLB:25807, KCLB:90358, LiGeA:CCL_423, LINCX_LDP:LCL-1671, Lonza:729, NCI-DTP:NCI-H358, PharmacDB:NCIH358_1110_2019, PRIDE:PX030304, Progenetix:CVCL_1559, PubChem_Cell_line:CVCL_1559, Wikidata:Q54908041

ID: CVCL_1559

Record Creation Time: 20220427T220840+0000

Record Last Update: 20260905T181245+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H358.

No alerts have been found for NCI-H358.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 532 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#).

- Pyun WY, et al. (2026) Nutrient Availability Dictates Cancer Metabolism-Based Therapeutic Responses to Nononcology Drugs. *Cancer research*, 86(5), 1194.
- Li J, et al. (2026) Lactylation Enhances the Activity of Lactate Dehydrogenase A and Promotes the Chemoresistance to Cisplatin Through Facilitating DNA Nonhomologous End Junction in Lung Adenocarcinoma. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(3), e10733.
- Jia A, et al. (2026) Dual targeting of SLC25A51 and succinate dehydrogenase selectively depletes mitochondrial NAD⁺ to eradicate KRAS-driven AML. *Cell metabolism*, 38(6), 1113.
- Zhang R, et al. (2026) Covalent modification of a glutamic acid inspired by HaloTag technology. *Nature communications*, 17(1), 1257.
- O'Toole KT, et al. (2026) Identification and characterization of BRAF^TTP53 interactions in melanoma. *Cell reports*, 45(4), 117078.
- Chuikov S, et al. (2026) E2A selectively regulates TGF- β -induced apoptosis in KRAS-mutant non-small cell lung cancer. *Molecular oncology*, 20(7), 1877.
- Ma X, et al. (2026) UFMylation-dependent inhibition of AKT signaling by PHLDA3 in lung adenocarcinoma. *Cell reports*, 45(4), 117154.
- Sohal IS, et al. (2026) Exosome-like biogenesis from the Golgi releases extracellular vesicles lacking conventional tetraspanins that mediate immune evasion in cancer. *bioRxiv : the preprint server for biology*.
- Hu Z, et al. (2026) Extracellular ATP-P2RY2 signaling drives intratumoral prostaglandin E2 accumulation and adaptive resistance to immunotherapy in solid tumors. *Immunity*, 59(7), 1928.
- Wei Y, et al. (2026) High-throughput ligand discovery in living cells using the cellular protein stability enhancement assay. *Acta pharmaceutica Sinica. B*, 16(7), 4524.
- Wang J, et al. (2026) Systematic annotation of orphan RNAs reveals blood-accessible molecular barcodes of cancer identity and cancer-emergent oncogenic drivers. *Cell reports. Medicine*, 7(2), 102577.
- O'Loughlin TA, et al. (2026) mTORC1 activity suppresses ferroptosis through a SCARB1-dependent HDL-tocopherol uptake pathway. *Molecular cell*, 86(8), 1546.
- Ning W, et al. (2026) A bispecific nanobody-drug conjugate targeting TROP2 and c-Met for low-concentration, single-dose treatment of pancreatic cancer. *Cell reports. Medicine*, 7(4), 102688.
- Stern YE, et al. (2026) Targeting CDK12/13 Drives Mitotic Arrest to Overcome Resistance to KRASG12C Inhibitors. *Cancer research*, 86(2), 485.
- Kwon YJ, et al. (2026) Basroparib inhibits YAP-driven cancers by stabilizing angiomin. *Molecular oncology*, 20(5), 1284.

Takeda S, et al. (2026) A MERTK-Targeting Antibody-Drug Conjugate Selectively Depletes M2 Tumor-Associated Macrophages and MERTK-Expressing Cancer Cells. *Cancer research*, 86(8), 2024.

Kanemura H, et al. (2026) Constitutive EGFR Activation Induced by PTPRR Downregulation Confers Resistance to KRAS Inhibitors. *Cancer research communications*, 6(4), 728.

Zhang R, et al. (2026) Targeting a Glutamic Acid in PDE γ with Fluoromethyl-Aryl Electrophiles Impairs K-Ras Signaling. *Journal of medicinal chemistry*.

Solanki HS, et al. (2026) RAS-GTP Inhibition Overcomes Acquired Resistance to KRASG12C Inhibitors Mediated by Oncogenic and Wild-Type RAS Activation in Non-Small Cell Lung Cancer. *Cancer research*, 86(2), 467.

Gupta I, et al. (2026) Correlation of the differential expression of PIK3R1 and its spliced variant, p55 γ , in pan-cancer. *Molecular oncology*, 20(5), 1299.